The New Jersey Tech Council (NJTC) recently honored OrthogenRx, a Doylestown-based medical device company, with the 2019 Innovative Company of the Year Award, sponsored by Rowan University and Yorktel.
The award was presented at NJTC’s 23rd annual award celebration. Awards were presented to technology and life sciences companies for collaboration, innovation, and leadership.
“Innovation is a team sport and the success of OrthogenRx is due to the key contributions of our team striving for excellence, dedication, and creativity.” Dr. Mike Daley, founder and CEO of OrthogenRx, said. “The award also reflects the recognition of our unprecedented success as a small company in bringing multiple products to market. The award, along with our promising pipeline, marks the journey of OrthogenRx fulfilling its vision of being the preeminent supplier of treatment solutions for musculoskeletal disorders.”
OrthogenRx develops treatments for musculoskeletal conditions. Two drugs, GenVisc 850 and TriVisc, are for the treatment of osteoarthritis pain in the knees of patients who have failed to respond adequately to non-pharmacologic therapy or simple analgesics.
The drugs were developed in collaboration with Japan’s Meiji Seika Pharma Co. and its manufacturing subsidiary, Meiji Farma Spain.
OrthogenRx has been a member of the NJTC for six years.